Abbott Neuromodulation

Quote



LOL! Flat sales for Abbott neuromod in Q4 - in a sector that is growing in mid-double digits. Boston is now officially dominating them. Not surprised with the culture that they created in Austin. Two more people left the marketing team in the last quarter.
 


anonymous said:
LOL! Flat sales for Abbott neuromod in Q4 - in a sector that is growing in mid-double digits. Boston is now officially dominating them. Not surprised with the culture that they created in Austin. Two more people left the marketing team in the last quarter.
Click to expand...

That's crazy! My financial advisor just told me that Boston Scientific Neuromodulation had 18% revenue growth during the same period. Looks like the exorbitant physician payments just can't make up for bad marketing anymore...
 


anonymous said:
LOL! Flat sales for Abbott neuromod in Q4 - in a sector that is growing in mid-double digits. Boston is now officially dominating them. Not surprised with the culture that they created in Austin. Two more people left the marketing team in the last quarter.
Click to expand...

Yah, I just heard that the VP of Marketing, Chris Bingham, got fired this week. With more turnover expected...
 


anonymous said:
Over $500k of the payments to Dr. Deer in 2016 were in the form of stock options...issued a few months prior to Abbott’s acquisition of St. Jude. 200% legit.
Click to expand...

You SJM slouches are lucky Abbott bailed your ass out. Nobody gives a shit about how the game is played. You’re on the sidelines and helpless. That $500k returned $10M easy. ADC dreads you SJM meter maids. Big business for Abbott and White knows the market. We’re gonna destroy BSX in due time. This better not be you Brinkman.
 


9% decline in sales in Q1 year over year - in a market where the competitors are growing at a double-digit rate... The chickens have finally come home to roost and the Abbott neuromodulation division is paying a huge price for the arrogance in upper management. You would think that changes in the senior management group are imminent after 3 dismal quarters, but Miles White is between a rock and a hard place. He can't fire Keith Boettiger, as he does not know anything about neuromodulation. At the same time, he might have an investor revolt on his hands if he does not get more out of a division where market growth is above 10% per year. The Q1 '19 results will probably force his hand. Or hopefully - not sure I want stock in a company where executive leadership can't make simple calls like this. The rot starts at the top.
 


anonymous said:
9% decline in sales in Q1 year over year - in a market where the competitors are growing at a double-digit rate... The chickens have finally come home to roost and the Abbott neuromodulation division is paying a huge price for the arrogance in upper management. You would think that changes in the senior management group are imminent after 3 dismal quarters, but Miles White is between a rock and a hard place. He can't fire Keith Boettiger, as he does not know anything about neuromodulation. At the same time, he might have an investor revolt on his hands if he does not get more out of a division where market growth is above 10% per year. The Q1 '19 results will probably force his hand. Or hopefully - not sure I want stock in a company where executive leadership can't make simple calls like this. The rot starts at the top.
Click to expand...
Is that right? I just had an interview with Boston Scientific and supposedly they grew 10% yoy during the same time. Abbott must really be struggling!
 








The freefall is now official. Abbott Neuromodulation sales declined almost 5% year over year in Q2 - in a market that is growing at mid-double digits. I guess Mr. Boettiger was always worried about getting taken seriously. I guess he can stop worrying now...
 


Hey at least they re launched proclaim 5 with all the Neuromod “young guns”
Jerking each other off on social media with the one Bold IPG they will put in and then go back to the better product they were using.
 




Bwahahahaha! Did I see correctly that ABT neuromod sales declined almost 3% year over year in the Q3 earnings announced last year? Medtronic, BSC and Nevro must be raking it in! Yet ABT continues with the same washed up airbags in upper management. What's the definition of insanity again? On the bright side, I guess the comps are looking good for some renewed posturing in 2020...
 


anonymous said:
Bwahahahaha! Did I see correctly that ABT neuromod sales declined almost 3% year over year in the Q3 earnings announced last year? Medtronic, BSC and Nevro must be raking it in! Yet ABT continues with the same washed up airbags in upper management. What's the definition of insanity again? On the bright side, I guess the comps are looking good for some renewed posturing in 2020...
Click to expand...

You were Duncan and Carl’s bitch, and got slapped!
 


anonymous said:
Bwahahahaha! Did I see correctly that ABT neuromod sales declined almost 3% year over year in the Q3 earnings announced last year? Medtronic, BSC and Nevro must be raking it in! Yet ABT continues with the same washed up airbags in upper management. What's the definition of insanity again? On the bright side, I guess the comps are looking good for some renewed posturing in 2020...
Click to expand...

Abbott sees Nevro as a small player who cannot make a dent in Neuromod sales - and if they do, Abbott can buy Nevro ... or so management believes
 




Abbott Neuromod is a clown show. 10% DECLINE yoy in sales in Q1. Nevro and BSX are legitimately mopping the floor with this division. I guess renaming Proclaim 3 times ended up not being a good long term marketing strategy...
 




Horrible culture - led by Mr. Boettiger. Once the commissions dried up, so did one of the last remaining reasons to stay. Nevro, Boston and Medtronic are all leapfrogging them. Not much of a future left at Abbott Neuromodulation.
 



Write your reply...
Top Bottom
Back
Quote